NYSEMKT: SDEVStablecoin Development Corp Stock
$1.74+0.04 (+2.35%)
Updated Apr 8, 2026
SDEV Price
$1.74
Fair Value Price
N/A
Market Cap
$46.33M
52 Week Low
$1.11
52 Week High
$99.75
P/E
-0.46x
P/B
-2x
P/S
N/A
PEG
N/A
Dividend Yield
0%
Revenue
$0.00
Earnings
-$22.14M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.38
Operating Cash Flow
-$8M
Beta
0.73
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SDEV Overview
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing products for the eye care market. The company is headquartered in Emeryville, California and currently employs 70 full-time employees. The firm focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. The company develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The firm's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SDEV's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SDEV
Ranked#367 of 459
Ranked#367 of 459
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $195.93 | A | |
| $23.62 | A | |
| $9.78 | A |
Be the first to know about important SDEV news, forecast changes, insider trades & much more!
SDEV News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SDEV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SDEV is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SDEV is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
SDEV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more SDEV due diligence checks available for Premium users.
Valuation
SDEV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.46x
Industry
29.95x
Market
29.79x
SDEV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2x
Industry
4.84x
SDEV's financial health
Profit margin
Revenue
-$521.0k
Net Income
-$26.6M
Profit Margin
5,104.8%
SDEV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$9.0M
Liabilities
$31.9M
Debt to equity
-1.38
SDEV's short-term assets ($8.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SDEV's long-term liabilities ($30.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SDEV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SDEV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.3M
Investing
$0.0
Financing
$7.8M
SDEV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SDEV vs Biotech Stocks
Stablecoin Development Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.